COVID-19 outcomes in sickle cell disease and sickle cell trait

Throughout the Coronavirus Disease 2019 (COVID-19) pandemic, understanding the effects of COVID-19 on persons with Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT) has garnered interest. Patients with SCD diagnosed with COVID-19 utilize the emergency department and are hospitalized at significa...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical haematology 2022-09, Vol.35 (3), p.101382-101382, Article 101382
Main Authors: Christian, Jana, Lanzkron, Sophie, Naik, Rakhi P.
Format: Article
Language:English
Subjects:
Anemia
Anemia, Sickle Cell - complications
Anemia, Sickle Cell - therapy
COVID-19
Humans
Hydroxyurea - therapeutic use
Risk Factors
Sickle cell
Sickle cell trait
Sickle Cell Trait - complications
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Throughout the Coronavirus Disease 2019 (COVID-19) pandemic, understanding the effects of COVID-19 on persons with Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT) has garnered interest. Patients with SCD diagnosed with COVID-19 utilize the emergency department and are hospitalized at significantly higher rates compared to the general population, with vaso-occlusive crisis and acute chest syndrome as the leading presentations. Whether SCD alone increases the likelihood of severe COVID-19 illness remains uncertain; however, potential risk factors for severe disease among patients with SCD include older age, frequent acute care visits for pain, haemoglobin SC disease, and pre-existing end-organ disease. SCT status may also influence COVID-19 outcomes, particularly among those with pre-existing co-morbidities. Corticosteroids in patients with SCD and COVID-19 should be used with extreme caution given strong associations between corticosteroid exposure and severe vaso-occlusive crisis, with prophylactic transfusion administered if corticosteroids are deemed necessary. Hydroxyurea may be protective in COVID-19.
ISSN:1521-6926
1532-1924
DOI:10.1016/j.beha.2022.101382